Upsher-Smith Laboratories Adds ITI-111 (Nasal Midazolam) to CN... - 28 June 2010 23:15

MAPLE GROVE, Minn., June 28 /PRNewswire-AsiaNet/ -- Second Deal in Six Months Expands CNS Portfolio to Four Programs Upsher-Smith Laboratories, Inc. today announced an agreement with Ikano Therapeutics, Inc. to obtain exclusive global rights to ITI-111, Ikano's nasal midazolam. Under...

  Dapagliflozin As Add On Therapy To Insulin Demonstrated Improv... - 27 June 2010 04:45

ORLANDO, Florida, June 27/ PRNewswire-AsiaNet/ -- - Not for US Media Results from a 24-week Phase 3 clinical study demonstrated that the addition of the investigational drug dapagliflozin achieved reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c), in in...

  Type 2 Diabetes Patients with Long-Standing Disease Achieved G... - 27 June 2010 01:18

ORLANDO, Fla., June 26 /PRNewswire-AsiaNet/ -- Study Presented at ADA 2010 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from the first double-blind, placebo-controlled clinical study to evaluate ex...

  Improvement in Beta-Cell Function Observed After Three Years o... - 27 June 2010 00:43

ORLANDO, Fla., June 26 /PRNewswire-AsiaNet/ -- Study Showed Improvements Compared to Insulin Glargine Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from a study comparing the effect of long-term treatment with eithe...

  Exenatide Once Weekly Safety and Tolerability Pooled Summary D... - 27 June 2010 00:18

ORLANDO, Fla., June 26 /PRNewswire-AsiaNet/ -- Data from Nearly 1,100 Patients in DURATION-1, -2 and -3 Trials Showed Exenatide Once Weekly was Well-Tolerated Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nas...

  ONGLYZA(TM) (saxagliptin) With Metformin As Initial Combinatio... - 26 June 2010 23:30

ORLANDO, Florida, June 26/PRNewswire-AsiaNet/ -- - Not for US Media Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results up to 76-weeks from a Phase 3 study of ONGLYZA(TM) (saxagliptin) as initial combination therapy with metformin, ...

  Kiwanis, UNICEF Join Forces to Save 129 Million Mothers and Ne... - 25 June 2010 08:41

LAS VEGAS, June 24 /PRNewswire-AsiaNet/ -- The Eliminate Project will protect mothers and babies from Tetanus Kiwanis International and UNICEF have joined forces to save the lives of babies and their mothers by eliminating maternal/neonatal tetanus (MNT), a disease that kills...

  China Pharma Events Attract Record Attendance - 24 June 2010 23:44

AMSTERDAM, June 24 /PRNewswire-AsiaNet/ -- Leading events organiser UBM International Media and sister company UBM Sinexpo today announced that a record attendance of 26,547 at its 2010 Chinese Pharma events cluster -- CPhI China for intermediates and APIs; P-MEC for equipment and mach...

  Progen Receives Delisting Notification from Nasdaq - 24 June 2010 13:06

BRISBANE, Australia, June 24 /Medianet International-AsiaNet/ -- Progen Pharmaceuticals Limited (ASX:PGL;NASDAQ:PGLA) today received notice from the Nasdaq Stock Market that its securities will be delisted due to a minimum bid price deficiency under Nasdaq Listing Rule 5500(a)(2). The notice states tha...

  ConvaTec Introduces Flexi-Seal(TM) SIGNAL(TM) FMS - 22 June 2010 17:00

SKILLMAN, N.J., June 22 /PRNewswire-AsiaNet/ -- A new solution from the Flexi-Seal(TM) FMS family of fecal management systems that helps clinicians seal their patients' protection ConvaTec, a world-leading developer and marketer of innovative medical technologies for commu...